Latest News and Press Releases
Want to stay updated on the latest news?
-
UTRECHT, The Netherlands, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today...
-
UTRECHT, The Netherlands, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced...
-
UTRECHT, Pays-Bas, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), une entreprise d'immuno-oncologie de stade clinique qui développe des traitements innovants à base d'anticorps...
-
UTRECHT, Niederlande, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), ein Unternehmen im Bereich der klinischen Immunonkologie, das innovative bispezifische Antikörpertherapeutika...
-
UTRECHT, The Netherlands, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced...
-
Raises $53.3 Million in Successful Initial Public Offering Doses First Patient in Phase 1/2 Study of MCLA-117 in Patients with AML UTRECHT, The Netherlands, July 12, 2016 (GLOBE NEWSWIRE) --...
-
BERLIN & UTRECHT, The Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today jointly announced that Merus has signed a commercial...
-
UTRECHT, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (“Merus”) (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today...
-
UTRECHT, the Netherlands, May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (“Merus”) (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial...
-
UTRECHT, the Netherlands, May 18, 2016 (GLOBE NEWSWIRE) -- Merus B.V. (“Merus”) today announced the pricing of its initial public offering of 5,500,000 common shares at an initial public offering...